219
Views
21
CrossRef citations to date
0
Altmetric
Original Article

In vitro susceptibility of isolates of Francisella tularensis from Turkey

, , &
Pages 337-341 | Received 05 Sep 2012, Accepted 15 Nov 2012, Published online: 18 Dec 2012

References

  • World Health Organization. WHO Guidelines on Tularemia. WHO/CDS/EPR/2007.7. Geneva: WHO; 2007.
  • Sjöstedt A. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann N Y Acad Sci 2007;1105:1–29.
  • Eliasson H, Broman T, Forsman M, Bäck E. Tularemia: current epidemiology and disease management. Infect Dis Clin North Am 2006;2:289–311.
  • Tarnvik A, Chu MC. New approaches to diagnosis and therapy of tularemia. Ann N Y Acad Sci 2007;1105:378–404.
  • Kudelina RI, Olsufiev NG. Sensitivity to macrolide antibiotics and lincomycin in Francisella tularensis holarctica. J Hyg Epidemiol Microbiol Immunol 1980;24:84–91.
  • Sandström G, Sjöstedt A, Forsman M, Pavlovich NV, Mishankin BN. Characterization and classification of strains of Francisella tularensis isolated in the central Asian focus of the Soviet Union and in Japan. J Clin Microbiol 1992;1: 172–5.
  • Enderlin G, Morales L, Jacobs R F, Cross JT. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis 1994;19:42–7.
  • Syrjala H, Schildt R, Raisainen S. In vitro susceptibility of Francisella tularensis to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacin. Eur J Clin Microbiol Infect Dis 1991;10:68–70.
  • Johansson A, Berglund L, Gothefors L, Sjostedt A, Tärnvik A. Ciprofloxacin for treatment of tularemia in children. Pediatr Infect Dis J 2000;19:449–53.
  • Johansson A, Berglund L, Sjostedt A, Tärnvik A. Ciprofloxacin for treatment of tularemia. Clin Infect Dis 2001; 33:267–8.
  • Meric M, Willke A, Finke EJ, Grunow R, Sayan M, Erdogan S, Gedikoglu S. Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia. APMIS 2008;116: 66–73.
  • Tomaso H, Al Dahouk S, Hoefer E, Splettstoesser W, Treu T, Dierich M, Neubauer H. Antimicrobial susceptibilities of Austrian Francisella tularensis holarctica biovar II strains. Int J Antimicrob Agents 2005;26:279–84.
  • Yesilyurt M, Kilic S, Celebi B, Celik M, Gul S, Erdogan F, Ozel G. Antimicrobial susceptibilities of Francisella tularensis subsp. holarctica strains isolated from humans in the Central Anatolia region of Turkey. J Antimicrob Chemother 2011;11:2588–92.
  • Sjöstedt A, Kuoppa K, Johansson A, Sandström G. The 17 kDa lipoprotein and encoding gene of Francisella tularensis LVS are conserved in 241 strains of Francisella tularensis. Microb Pathog 1992;13:243–9.
  • Broekhuijsen M, Larsson P, Johansson A, Bystrom M, Eriksson U, Larsson E, et al. Genome-wide DNA microarray analysis of Francisella tularensis strains demonstrates extensive genetic conservation within the species but identifies regions that are unique to the highly virulent F. tularensis subsp. tularensis. J Clin Microbiol 2003;7:2924–31.
  • Huber B, Escudero R, Busse HJ, Seibold E, Scholz HC, Anda P, et al. Description of Francisella hispaniensis sp. nov., isolated from human blood, reclassification of Francisella novicida (Larson et al. 1955) Olsufiev et al. 1959 as Francisella tularensis subsp. novicida comb. nov. and emended description of the genus Francisella. Int J Syst Evol Microbiol 2010;60:1887–96.
  • Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. CLSI document M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
  • Ikäheimo I, Syrjälä H, Karhukorpi J, Schildt R, Koskela M. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J Antimicrob Chemother 2000;46:287–90.
  • Eric V, Vaissaire J, Merens A, Hernandez E, Gros C, Le Doujet C, et al. Susceptibility of 71 French isolates of Francisella tularensis subsp. holarctica to eight antibiotics and accuracy of the E test method. J Antimicrob Chemother 2008;1:208–10.
  • García del Blanco N, Gutiérrez Martín CB, de la Puente Redondo VA, Rodríguez Ferri EF. In vitro susceptibility of field isolates of Francisella tularensis subsp. holarctica recovered in Spain to several antimicrobial agents. Res Vet Sci 2004;76:195–8.
  • Johansson A, Urich SK, Chu MC, Sjöstedt A, Tärnvik A. In vitro susceptibility to quinolones of Francisella tularensis subspecies tularensis. Scand J Infect Dis 2002;34:327–30.
  • Scheel O, Hoel T, Sandvik T, Berdal BP. Susceptibility pattern of Scandinavian Francisella tularensis isolates with regard to oral and parenteral antimicrobial agents. APMIS 1993;101:33–6.
  • Urich SK, Petersen JM. In vitro susceptibility of isolates of Francisella tularensis types A and B from North America. Antimicrob Agents Chemother 2008;6:2276–8.
  • Aranda EA. Treatment of tularemia with levofloxacin. Clin Microbiol Infect 2001;7:167–8.
  • Scheel O, Reiersen R, Hoel T. Treatment of tularemia with ciprofloxacin. Eur J Clin Microbiol Infect Dis 1992;11: 447–8.
  • Harrell RE Jr, Simmons HF. Pleuropulmonary tularemia: successful treatment with erythromycin. South Med J 1990; 83:1363–4.
  • Westerman EL, McDonald J. Tularemia pneumonia mimicking legionnaires’ disease: isolation of organism on CYE agar and successful treatment with erythromycin. South Med J 1983;76:1169–70.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.